| (1S,2R)-Boc-2-amino-1-cyclopentanecarboxylic acid |
2-BOC-氨基环戊酸 |
245115-25-7 |
| FMOC-N-(BUTYL)-GLYCINE |
N-FMOC-N-丁基甘氨酸 |
234442-58-1 |
| SRPK inhibitor |
SRPKINHIBITOR |
218156-96-8 |
| ReModelin hydrobroMide |
REMODELIN |
1622921-15-6 |
| NIBR189 |
NIBR189 |
1599432-08-2 |
| XEN445 |
(S)-2-(3-(PYRIDIN-2-YLMETHOXY)PYRROLIDIN-1-YL)-5-(TRIFLUOROMETHYL)BENZOIC ACID. HCL |
1515856-92-4 |
| UNC2025 |
反式-4-[2-(丁基氨基)-5-[4-[(4-甲基-1-哌嗪基)甲基]苯基]-7H-吡咯并[2,3-D]嘧啶-7-基]-环己醇 |
1429881-91-3 |
| Tazemetostat (EPZ-6438) |
EPZ-6438 |
1403254-99-8 |
| BIX 01294 |
BIX 01294三盐酸盐水合物 |
1392399-03-9 |
| Verdinexor (KPT-335) |
Verdinexor (KPT-335) |
1392136-43-4 |
| CO-1686 |
CO1686 |
1374640-70-6 |
| BRD4770 |
2-苯甲酰胺基-1-(3-苯丙基)-1H-苯并[D]咪唑-5-羧酸甲酯 |
1374601-40-7 |
| ON123300 |
8-环戊基-7,8-二氢-2-[[4-(4-甲基-1-哌嗪基)苯基]氨基]-7-氧代-吡啶并[2,3-D]嘧啶-6-甲腈 |
1357470-29-1 |
| PI3K/HDAC Inhibitor |
CUDC-907 |
1339928-25-4 |
| N-(5-(1-(2,6-dichlorophenyl)-3-(difluoroMethyl)-1H-pyrazol-5-yl)thiazol-2-yl)cyclopropanecarboxaMide |
BMS-3 |
1338247-30-5 |
| Tubastatin A hydrochloride |
Tubastatin A盐酸盐 |
1310693-92-5 |
| LGK-974 |
2',3-二甲基-N-[5-(2-吡嗪基)-2-吡啶基]-[2,4'-联吡啶]-5-乙酰胺 |
1243244-14-5 |
| FMOC-GLN(TRT)-SER(PSI-ME,MEPRO)-OH |
FMOC-GLN(TRT)-SER(PSI(ME,ME)PRO)-OH |
1821378-64-6 |
| ACK1-B19 |
5,11-二氢-2-((2-甲氧基-4-(4-甲基-1-哌嗪基)苯基)氨基)-11-甲基-6H-嘧啶并[4,5-B][1,4]苯并二氮杂卓-6-酮 |
1234480-46-6 |
| 2-[[2-Ethoxy-4-(4-hydroxy-1-piperidinyl)phenyl]amino]-5,11-dihydro-5,11-dimethyl-6H-pyrimido[4,5-b][1,4]benzodiazepin-6-one |
2-[[2-乙氧基-4-(4-羟基-1-哌啶基)苯基]氨基]-5,11-二氢-5,11-二甲基-6H-嘧啶并[4,5-B][1,4]苯并二氮杂卓-6-酮 |
1234480-50-2 |
QQ
微信
